Shingles Live Attenuated Vaccine, Ganwei®
Category:
Detailed introduction
Product Name: Live Attenuated Zoster Vaccine
Product Name: Ganwei®
National Drug Approval Number: S20233097
Introduction:
●Expanded age group
According to CDC data, 30% of individuals will develop shingles at some point in their lives. As age increases, the prevalence of VZV IgG antibodies rises steadily, with over 98% of people aged 40 and older testing positive for these antibodies, indicating that the risk of shingles increases with advancing age. Furthermore, a 20-year retrospective analysis from the Asia-Pacific region shows that the incidence of shingles begins to rise after the age of 40. Ganwei® is an attenuated live vaccine indicated for individuals aged 40 and above, filling the vaccination gap for this age group and thereby benefiting a larger population.
● Get vaccinated early, reap the benefits early
Currently, there is a trend toward younger onset of herpes zoster. After the age of 40, VZV-specific cellular immune function declines markedly; the younger the individual, the stronger the immune response to vaccination. Therefore, the earlier the vaccine is administered, the sooner the benefits are realized.
● One dose works—safe and worry-free
Compared with the two-dose regimen of imported vaccines, BCG Biotech’s live attenuated shingles vaccine requires only a single dose, making it more convenient and cost-effective. In terms of safety, the incidence of common adverse reactions such as fever is less than 10%, providing patients with greater peace of mind during vaccination.
Keywords:
Previous page:
Next page:
Online Quotation
Please provide your phone number and email address, and we’ll get in touch with you as soon as possible.